Academic Perspectives for the Management of HPV-Positive HNSCC

Author(s):

Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center,Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Panelists discuss how human papillomavirus (HPV)–related tumors vary in aggressiveness, with HPV-positive head and neck squamous cell carcinoma (HNSCC) presenting unique challenges. Key treatment hurdles include tumor heterogeneity, resistance development, and optimizing de-escalation strategies while maintaining efficacy.

EP: 1.Introduction and Incidence of HPV-Positive Head and Neck Cancer

EP: 2.Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors

EP: 3.Navigating Treatment for HPV-Positive HNSCC Patients

Now Viewing

EP: 4.Academic Perspectives for the Management of HPV-Positive HNSCC

EP: 5.Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC

EP: 6.Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)

EP: 7.Treatment Insights for R/M HPV-Positive HNSCC

EP: 8.Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Video content above is prompted by the following:

Are certain types of HPV-related tumors more difficult to treat or more aggressive than others?
What are the primary challenges clinicians face when treating HPV-positive HNSCC?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!